ArticleBMC cancer2025
Association of estimated glucose disposal rate with all-cause and breast cancer-specific mortality in US breast cancer survivors: a population-based study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInsulin resistance (IR) is increasingly linked with poor cancer prognosis, but its impact on mortality among breast cancer patients—particularly regarding different causes of death—remains incompletely understood. The estimated glucose disposal rate (eGDR) is a surrogate index of insulin sensitivity. This study intended to investigate the links of eGDR with all-cause mortality (ACM) and breast cancer-specific mortality (BCSM) in US breast cancer survivors.
methodsData were sourced from the 2007–2016 National Health and Nutrition Examination Survey(NHANES). A cross-sectional design was used to assess the link between eGDR and breast cancer prevalence, while a cohort design was adopted for mortality follow-up. Additionally, weighted logistic regression was leveraged to estimate the link between eGDR and breast cancer prevalence. Cox models were employed to evaluate the relationship between eGDR and ACM. Restricted cubic splines were utilized to model nonlinear links, and competing risk models were adopted to analyze BCSM.
resultsAmong 323 women with breast cancer, 73 deaths occurred during follow-up (median 6.2 years). After multiple confounders were controlled, a binary analysis using optimal cutoff values confirmed that higher eGDR was independently linked with lower ACM risk (HR: 0.40; 95% CI: 0.18–0.89; P = 0.025). This association was nonlinear, and the protective effect remained across multiple subgroups. In competing risk analysis, a potential association was observed between higher eGDR and lower BCSM risk (HR: 0.13; 95% CI: 0.02–0.99; P = 0.048), with no marked association observed for cardiovascular mortality.
conclusionIn US breast cancer survivors, higher eGDR was independently linked with lower ACM risk. This association may be partly driven by a reduction in BCSM, but this specific finding requires validation in larger studies due to considerable statistical uncertainty.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.